Arm 2: Alisertib + Fulvestrant
PD, death, neutropenia
NEUTROPENIA, SECOND PRIMARY CANCER
Two of 45 patients continued to receive alisertib with fulvestrant as of the data lock. Reasons for discontinuing treatment included PD (31 [68.9%]), intolerability (6 [13.3%]), refusal (4 [8.9%]), second primary cancer (1 [2.2%]), and death (1 [2.2%]). The median treatment cycles completed was 4 (range, 1-44). Sixteen patients (35.6%) required at least 1 dose reduction within the first year, most commonly due to neutropenia. Per One complete response and 8 partial responses were observed (